Introduction. Benign prostatic hyperplasia (BPH) and chronic prostatitis (CP) are among the most important urological diseases. The right choice of treatment for patients with BPH and CP continues to be contradictory. Recently, a new group of entomological drugs has been increasingly used, one of which is Adenoprosin®.
Aim. To study the efficiency of Adenoprosin® as part of combination therapy, as well as to evaluate the long-term outcomes in patients with BPH and CP.
Materials and methods. A total of 60 patients with BPH and CP were included in the study. They were randomized into two groups of 30 each. In the comparison group, traditional therapy with α1-blockers and fluoroquinolones was administered. In the main group, similar therapy was prescribed in combination with Adenoprosin for 6 months. The follow-up period was 12 months.
Results. At baseline, the groups were homogeneous. After three and six months, the results in the control group did not significantly improve, but negative dynamics was revealed at visit 4. The results obtained in the main group at visits 3 and 4 were also significantly better (p<0.05) compared to the control group. During 12 months of follow–up, 7 (23.3%) cases of recurrent CP in the comparison group and 1 (3.3%) case in the main group were seen.
Conclusion. According to our results, the use of Adenoprosin® for 6 months allowed more effectively to reduce the lower urinary tract symptoms. The obtained effect persisted for the next 6 months, as evidenced by the dynamics of the studied indicators and the relapse rate of CP.

Keywords: Adenoprosin, entomological drugs, benign prostatic hyperplasia, chronic prostatitis